Dicerna Pharmaceuticals, Inc.: visa sponsorship and H-1B record
No open jobs from Dicerna Pharmaceuticals, Inc. on VisaJob.us right now. Browse all visa sponsorship jobs.
Sponsorship history
Sponsors actively| Fiscal year | H-1B LCAs | USCIS approvals | USCIS denials | PERM |
|---|---|---|---|---|
| FY2025 | 8 | 6 | 0 | 1 |
| FY2024 | 6 | 10 | 0 | — |
Roles they sponsor most
- analyst fp a1 LCA · median $105k
- assoc computational biologist1 LCA · median $109k
- assoc scientist discovery research1 LCA · median $108k
- associate scientist1 LCA · median $105k
- research associate1 LCA · median $85k
- research associate adme1 LCA · median $94k
- research associate rnai discovery1 LCA · median $75k
- scientist1 LCA · median $119k
- scientist1 LCA · median $150k
- scientist1 LCA · median $145k
- scientist chem dev1 LCA · median $130k
- scientist medicinal chemistry1 LCA · median $130k
- scientist rna gene therapy1 LCA · median $150k
- scientist translational biology1 LCA · median $120k
FAQ
Does Dicerna Pharmaceuticals, Inc. sponsor H-1B visas?
Yes. Dicerna Pharmaceuticals, Inc. filed 14 H-1B labor condition applications in the years covered by our data, 14 of them certified by the Department of Labor.
Does Dicerna Pharmaceuticals, Inc. sponsor green cards?
Yes. Dicerna Pharmaceuticals, Inc. filed 1 PERM labor certifications, the first step of most employment-based green cards; 1 were certified.
Is Dicerna Pharmaceuticals, Inc. cap-exempt?
Dicerna Pharmaceuticals, Inc. appears to be a regular cap-subject employer, so new H-1B workers need to be selected in the annual lottery.
Sources: U.S. Department of Labor OFLC disclosure data (H-1B/H-1B1/E-3 LCA, PERM), OFLC prevailing wage data, USCIS H-1B Employer Data Hub, E-Verify participating employers. Data loaded: LCA FY2024–FY2026, PERM, USCIS Data Hub, OFLC wages; updated 2026-10-03. Employers are matched by name, so records of companies with similar names can occasionally be mixed up. This is general information, not legal advice — talk to an immigration attorney about your case.